Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Michael Greene who wrote (1678)	1/25/1999 5:13:00 PM
From: Biomaven	Read Replies (1) \| Respond to of 10280

Michael, As I posted previously, I believe the Knoll composition of matter patent is due to expire in 2002 - it took umpteen years before they figured out it worked as a weight-loss drug and to get it approved. Knoll has recently applied for an automatic 5 year extension based on the time it spent getting regulatory approval. However, this extension may not impact SEPR's use of an active metabolite of sibutramine. Knoll also has a whole bunch of use patents (like for weight-loss) with much later expiration dates. I'm not sure what the impact of these on SEPR is - arguably nothing. Peter